Abstract
Does benefits of rivaroxaban as add-on to aspirin apply to diabetes-related cardiovascular disease? Insights from the COMPASS and VOYAGER PAD trials
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Diabetes in Developing Countries
Paper Title
Journal
Date
